Xbrane Biopharma AB (XBRANE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xbrane Biopharma AB (XBRANE) has a cash flow conversion efficiency ratio of -0.009x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.82 Million ≈ $-518.82K USD) by net assets (Skr538.85 Million ≈ $57.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see XBRANE market cap overview for the company's overall valuation and market capitalisation.
Xbrane Biopharma AB - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Xbrane Biopharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xbrane Biopharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xbrane Biopharma AB ranked by their cash flow conversion efficiency. Explore Xbrane Biopharma AB cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DAP Corporation
KQ:066900
|
-0.045x |
|
Studio Mir Co. Ltd.
KQ:408900
|
-0.036x |
|
Caldwell Partners International Inc
TO:CWL
|
-0.159x |
|
Hamashbir 365 Holdings Ltd
TA:MSBI
|
0.659x |
|
Isofol Medical AB
ST:ISOFOL
|
-0.100x |
|
HG Capital Trust PLC
LSE:HGT
|
-0.016x |
|
Ratio Energies LP
TA:RATI-L
|
0.145x |
|
Investors House
HE:INVEST
|
-0.089x |
Annual Cash Flow Conversion Efficiency for Xbrane Biopharma AB (2013–2025)
The table below shows the annual cash flow conversion efficiency of Xbrane Biopharma AB from 2013 to 2025. View Xbrane Biopharma AB (XBRANE) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr560.65 Million ≈ $60.34 Million |
Skr-250.69 Million ≈ $-26.98 Million |
-0.447x | +30.27% |
| 2024-12-31 | Skr208.54 Million ≈ $22.44 Million |
Skr-133.73 Million ≈ $-14.39 Million |
-0.641x | +72.98% |
| 2023-12-31 | Skr171.34 Million ≈ $18.44 Million |
Skr-406.68 Million ≈ $-43.77 Million |
-2.374x | -420.07% |
| 2022-12-31 | Skr424.89 Million ≈ $45.72 Million |
Skr-193.92 Million ≈ $-20.87 Million |
-0.456x | +10.27% |
| 2021-12-31 | Skr431.74 Million ≈ $46.46 Million |
Skr-219.61 Million ≈ $-23.63 Million |
-0.509x | +45.02% |
| 2020-12-31 | Skr257.71 Million ≈ $27.73 Million |
Skr-238.41 Million ≈ $-25.66 Million |
-0.925x | -14.76% |
| 2019-12-31 | Skr184.32 Million ≈ $19.84 Million |
Skr-148.59 Million ≈ $-15.99 Million |
-0.806x | -243.37% |
| 2018-12-31 | Skr83.07 Million ≈ $8.94 Million |
Skr46.71 Million ≈ $5.03 Million |
0.562x | +234.89% |
| 2017-12-31 | Skr88.41 Million ≈ $9.51 Million |
Skr-36.85 Million ≈ $-3.97 Million |
-0.417x | -13.44% |
| 2016-12-31 | Skr107.30 Million ≈ $11.55 Million |
Skr-39.43 Million ≈ $-4.24 Million |
-0.367x | -40.93% |
| 2015-12-31 | Skr47.51 Million ≈ $5.11 Million |
Skr-12.39 Million ≈ $-1.33 Million |
-0.261x | +38.46% |
| 2014-12-31 | Skr6.30 Million ≈ $677.75K |
Skr-2.67 Million ≈ $-287.16K |
-0.424x | -67.55% |
| 2013-12-31 | Skr8.69 Million ≈ $935.17K |
Skr-2.20 Million ≈ $-236.48K |
-0.253x | -- |
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adu… Read more